ArticleBrain communications2025
Five-year disease-modifying therapeutic experience of 102 Chinese paediatric 5q-spinal muscular atrophy: a retrospective analysis.
Article in Brain communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
5q-spinal muscular atrophy (SMA) is a fatal autosomal recessive disease characterized by the progressive muscle weakness and atrophy. In this retrospective study, we described the long-term clinical outcomes of novel disease-modifying therapies (DMTs) for 5q-spinal muscular atrophy, drawing on experience from southern China. This is a single-centre large cohort which enrolled 102 paediatric patients confirmed with 5q-spinal muscular atrophy at Guangzhou Women and Children's Medical Center from 2019 to 2024. One hundred and two patients were included, 24 were classified as SMA type 1, 56 with type 2 and 22 with type 3. One hundred per cent of the patients received nusinersen, with 31 (30.3%) patients starting risdiplam and 2 patients transitioning to zolgensma therapy. Over the 5-year treatment and follow-up period (2019-24), the survival rate reached 97.08%. One child with SMA type 1 and two with SMA type 2 died while receiving nusinersen monotherapy. Compared with baseline, the enrolled SMA patients exhibited statistically significant motor function gains. Nevertheless, type 1 patients experienced weight loss, while linear growth was compromised in both type 1 and type 2 patients after treatment. Serum insulin-like growth factor-1 levels rose modestly in types 1 and 2, but the increase did not reach statistical significance. Respiratory tract infections, malnutrition, scoliosis and fracture are the main complications and potential life-threatening risk factors during DMTs. Moreover, longer diagnostic to treatment intervals were significantly and inversely associated with motor function gains and directly associated with higher complication rates. This retrospective study confirms the effectiveness of nusinersen and risdiplam for 5q-spinal muscular atrophy and highlights the critical importance of early initiation of DMTs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.